Evidence map›Paper›PMID 35111072›Full record

ReviewFrontiers in pharmacology2021

Use of a Fission Yeast Platform to Identify and Characterize Small Molecule PDE Inhibitors.

Charles S Hoffman

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Charles S HoffmanBiology Department, Boston College, Chestnut Hill, MA, United States.
Boston College · US

Funding

Pharmacologic Inhibition of PDE11A for Age-Related Memory DisordersR01AG067836 · NIA · MONTCLAIR STATE UNIVERSITY · PI HOFFMAN, CHARLES S., KELLY, MICHY PATRICE · 2020 to 2024
$3.6M
An in vivo screen for biological and chemical regulators of mammalial PDEsR21GM079662 · NIGMS · BOSTON COLLEGE · PI HOFFMAN, CHARLES S. · 2007 to 2008
$427k
NIA NIH HHS R01 AG067836NIGMS NIH HHS R21 GM079662
6 · The paper itself

Abstract

Cyclic nucleotide phosphodiesterases (PDEs) have been proven to be targets for which highly selective and potent drugs can be developed. Mammalian genomes possess 21 genes whose products are pharmacologically grouped into 11 families; however related genes from pathogenic organisms display sufficient divergence from the mammalian homologs such that PDE inhibitors to these enzymes could be used to treat parasitic infections without acting on the related human PDEs. We have developed a platform for expressing cloned PDEs in the fission yeast

Indexed as

Caenorhabditis eleganshigh throughput screen (HTS)inflammationparasitic nematodesphosphodiesteraseSchizosaccharomyces pombeselective PDE inhibitors

Identifiers

PMID35111072
PMCPMC8802716
OpenAlexW4205791233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.